<DOC>
	<DOCNO>NCT00715780</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate incidence major hypoglycaemic episode adverse event , evaluate efficacy use insulin normal clinical practice condition . The switch OAD treatment insulin therapy determine physician .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Efficacy Insulin Therapy Type 2 Diabetes Mellitus Subjects Failing Oral Anti-diabetic Agents</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Type 2 diabetes least 12 month currently receive oral antidiabetic ( OAD ) treatment , whether single combination , least 3 month study Insulin naive Poor glycaemic control OADs decide physician start insulin therapy Type 1 diabetes patient Patients unlikely comply protocol , e.g. , uncooperative attitude , inability return final visit Patients hypersensitivity insulin excipients Patient group approve product label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>